| Date Filed | Type | Description |
| 08/18/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 07/14/2023 |
8-K
| Quarterly results |
| 07/03/2023 |
10-K/A
| Annual Report for the period ended March 31, 2023 [amend] |
| 06/29/2023 |
10-K
| Annual Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Nascent Biotech to Present Phase I Clinical Data at American Society of Clinical Oncology Annual Meeting NORTH PALM BEACH, FL, May 9, 2023 - Nascent Biotech, Inc. , a clinical-stage biotechnology Company whose business is focused in therapeutic monoclonal antibody space, announced today that the Company has been selected for a poster presentation at the American Society of Clinical Oncology 2023 Annual Meeting held in Chicago on June 2-6, 2023. The poster presentation, entitled ”Phase I Study of Pritumumab in Brain Cancer”, will take place from 1:15-4:15 PM CDT on June 3rd , during the ”Central Nervous Systems Tumors” session in Hall A of McCormick Place Convention Center. ASCO is the largest clinical oncology conference that brings together cancer leaders from across the globe to discuss ..." |
|
| 04/14/2023 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 02/14/2023 |
10-Q
| Quarterly Report for the period ended December 31, 2022 |
| 01/03/2023 |
SC 13G/A
| YA II PN, Ltd. reports a 10% stake in Nascent Biotech Inc. |
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 09/28/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 09/27/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 09/20/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 09/19/2022 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 09/09/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 09/06/2022 |
8-K/A
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 09/02/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 09/02/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/30/2022 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 08/09/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 06/15/2022 |
10-K
| Annual Report for the period ended March 31, 2022 |
| 02/14/2022 |
10-Q
| Quarterly Report for the period ended December 31, 2021 |
| 11/04/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 08/17/2021 |
8-K
| Other Events |
| 08/12/2021 |
10-Q
| Quarterly Report for the period ended June 30, 2021 |
| 07/08/2021 |
10-K
| Annual Report for the period ended March 31, 2021 |
| 06/29/2021 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 06/21/2021 |
SC 13G
| Lorio Sidney J Jr reports a 6.8% stake in Nascent Biotech Inc. |
| 06/17/2021 |
8-K
| Quarterly results |
| 05/11/2021 |
8-K
| Quarterly results |
| 04/26/2021 |
8-K
| Quarterly results |
| 04/14/2021 |
8-K
| Quarterly results |
| 03/24/2021 |
8-K
| Quarterly results |
| 02/09/2021 |
10-Q
| Quarterly Report for the period ended December 31, 2020 |
|